Jointown released its 2026 semi-annual report, with first-half attributable net profit of about 1.201 billion yuan, down 16.95% year on year. The company achieved operating revenue of about 87.279 billion yuan in the same period, up 7.61% year on year. Jointown said the revenue growth was mainly driven by continued growth in digital distribution and supply chain business and the results of strategic transformation, with B2C e-commerce and pharmaceutical industrial self-operated business up 19.1% and 24.47% year on year respectively, and medical devices, traditional Chinese medicine, and medical aesthetics business up 15.03%, 26.86%, and 64.99% year on year respectively. The decline in attributable net profit was mainly affected by a year-on-year decrease in non-recurring gains and losses, with non-recurring gains and losses of about 218 million yuan in this reporting period, a year-on-year decrease of about 276 million yuan.
Jointown Pharmaceutical Group Co LtdFirst-half attributable net profit fell 16.95% year on year due to lower non-recurring gains.
